Etilamfetamine

Pharmacology

Pharmacodynamics

Monoamine releasing agent

Ethylamphetamine is a potent dopamine releasing agent (DRA) in vitro, with an of 88.5nM. This is about 10-fold lower than the EC50 of dextroamphetamine. The EC50 values of ethylamphetamine for induction of norepinephrine and serotonin release were not reported. However, the EC50 values of its dextrorotatory enantiomer dextroethylamphetamine have been reported and were 44.1nM, 28.8nM, and 333nM for norepinephrine, dopamine, and serotonin, respectively. Hence, dextroethylamphetamine acts as a norepinephrine–dopamine releasing agent (NDRA) with weak effects on serotonin.

In terms of structure–activity relationships, the potency of amphetamines as dopamine releasing agents and reuptake inhibitors decreases with increasing N-alkyl chain length. That is, the order of potency of N-alkylated amphetamines is as follows: amphetamine methamphetamine ethylamphetamine propylamphetamine butylamphetamine. Propylamphetamine is a weak dopamine reuptake inhibitor rather than releaser, whereas butylamphetamine is completely inactive as a dopamine releaser or reuptake inhibitor. The same relationship, for monoamine release and reuptake inhibition generally, has been shown with 4-methylamphetamine and its N-alkylated derivatives like 4-methylmethamphetamine and so forth.

Other actions

Ethylamphetamine is inactive as an agonist of the mouse and human trace amine-associated receptor 1 (TAAR1), whereas findings in the case of the rat TAAR1 are conflicting. In one study, its Ki was 2,500nM and its () was 880nM (62%) at the rat TAAR1 (i.e., it was a partial agonist), whereas its Ki and/or EC50 values at the mouse and human TAAR1 were 10,000nM. In another study however, ethylamphetamine showed very little capacity to activate the rat TAAR1.

Pharmacokinetics

Ethylamphetamine can be N-dealkylated into amphetamine (5–18% excreted in urine after 24hours). As such, amphetamine may contribute to its effects in vivo.

Chemistry

The molecular structure of ethylamphetamine is analogous to methamphetamine, with an ethyl group in place of the methyl group.Amphetamine is a substituted phenethylamine with a methyl group at RA position. It can also be considered a substituted amphetamine, with an ethyl group on the amphetamine backbone.The ethyl group of ethylamphetamine is at RN position, hence the name N-ethylamphetamine.Ethylamphetamine is structurally similar to N-methylamphetamine (methamphetamine), the ethyl group being replaced in methamphetamine with a methyl group.

Analogues of ethylamphetamine include amphetamine, methamphetamine, propylamphetamine, isopropylamphetamine, butylamphetamine, fenfluramine (3-trifluoromethyl-N-ethylamphetamine), dimethylamphetamine, and 3-fluoroethamphetamine (3-fluoro-N-ethylamphetamine), among others.

Society and culture

Recreational use

Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though it is of lower potency.

Notes

References

References

1. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (October 1956). "L'éthylamphétamine dans le traitement de l'obésité". Praxis.
3. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug Alcohol Depend.
4. (March 2024). "Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones". Neuropharmacology.
5. Nicole, Lauren. (2022). "In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones".
6. (September 2017). "N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability". Neuropsychopharmacology.
7. Sakloth, Farhana. (11 December 2015). "Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action".
8. Forsyth, Andrea N. (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines".
9. (July 2008). "Dopamine Transporters: Chemistry, Biology and Pharmacology". Wiley.
10. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse.
11. (March 2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology.
12. (1999). "Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc".
13. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology.
14. (October 2003). "Monoamine transporters and psychostimulant drugs". European Journal of Pharmacology.
15. (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry.
16. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
17. (December 2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Mol Pharmacol.
18. (October 1973). "The effect of N-alkyl chain length of stereochemistry on the absorption, metabolism and during excretion of N-alkylamphetamines in man". J Pharm Pharmacol.